Survival after introduction of HAART in people with known duration of HIV-1 infection

Lancet

Volumn 355, Issue 9210, 2000, Pages 1158-1159

  Porter, K ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROCONVERSION; SHORT SURVEY; SURVIVAL;

EID: 0034176668     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02069-9     Document Type: Article

References (4)

1. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a pooled cohort analysis. Lancet. 355:2000;1131-1137.
2. Egger M., Hirschel B., Francioli P.et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland. prospective multicentre study BMJ. 315:1997;1194-1199.
3. Mocroft A., Vella S., Benfield T.L.et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 352:1998;1725-1730.
4. Detels R., Muñoz A., McFarlane G.et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 17:1998;1497-1503.